At the ASCO Annual Meeting in June 2011, we presented complete results from our Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of patients with advanced solid tumors with liver involvement.
Read our press release ALN-VSP PhI ClinicalStudyResults-ASCO2011 (1.2MB PPT) ALN-VSP RNAi Roundtable, May 2011 (2.2 MB PPT) Listen to Dr. Jared Gollob discuss ALN-VSP data at ASCO 2011 (3.1MB MP3)
Data presented showed that ALN-VSP was generally well tolerated and showed evidence for anti-tumor activity. Importantly, ALN-VSP was found to mediate RNAi activity in both hepatic and extra-hepatic tumors. We are very encouraged by these results, as they represent an important milestone in the advancement of RNAi therapeutics – showing for the first time both clinical activity and proof of the RNAi mechanism in man with an RNAi therapeutic.
